Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil, Allantoin Comparing With Topical 1% Hydrocortisone Cream

Sponsor
Mahidol University (Other)
Overall Status
Completed
CT.gov ID
NCT04325490
Collaborator
HOE pharmaceuticals Sdn. Bhd. (Other)
40
1
2
12
3.3

Study Details

Study Description

Brief Summary

A randomized controlled trial of efficiency and safety of liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin comparing with topical 1% hydrocortisone cream for the treatment of intertrigo

Condition or Disease Intervention/Treatment Phase
  • Drug: Liquid powder
  • Drug: Hydrocortisone cream 1%
Phase 4

Detailed Description

Intertrigo is an inflammatory dermatosis involving body folds that develops through friction of skin to skin and is influenced by moist conditions. The prevalence of intertrigo was reported to be 2.5% for adults with an average age of 41.5 years. Prevalence of intertrigo in the large skin folds varies from 6% in hospital patients to 17% in nursing home clients and 20% in home care patients. The inframammary fold was most often affected (9.9%), followed by the inguinal region (9.4%), axilla (0.5%) and abdominal region (0.5%). Intertrigo may be mild and asymptomatic, but also may lead to intense erythema and desquamation. The affected skin may have a foul odor and may be macerated and ulcerated with copious or purulent discharge. The conventional therapy for simple intertrigo is minimizing moisture and friction. Some suggest the use of absorptive powders, such as talc and cornstarch, or barrier creams. These topical treatments such as topical steroid, however, have little or no proven benefit and may cause irritation or facilitate yeast colonization. This study aims to evaluate the efficacy and safety of liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin comparing with topical 1% hydrocortisone cream of mild to moderate intertrigo patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A double-blined, randomized studyA double-blined, randomized study
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
the two interventions were prepared in an identical neutral package. The same investigator evaluated the skin condition at each follow-up visit. Patients were followed up at 2 weeks.
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Trial of Efficiency and Safety of Liquid Powder Containing Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil and Allantoin Comparing With Topical 1% Hydrocortisone Cream for Treatment of Intertrigo
Actual Study Start Date :
Oct 1, 2019
Actual Primary Completion Date :
Sep 30, 2020
Actual Study Completion Date :
Sep 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Liquid powder

Liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin on the selected intertrigo area.

Drug: Liquid powder
apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.

Active Comparator: Hydrocortisone

1% hydrocortisone cream

Drug: Hydrocortisone cream 1%
apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.

Outcome Measures

Primary Outcome Measures

  1. Efficacy of liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin, compared to topical 1% hydrocortisone cream for the treatment of intertrigo. [2 weeks]

    Efficacy was evaluated by the number of patients with improvement in erythema scores on intertrigo lesion after treatment which were assessed by the patients and the same investigator. Erythema scores were recorded using a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) on intertrigo lesion at baseline and week 2.

Secondary Outcome Measures

  1. Side effects of liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin, compared to topical 1% hydrocortisone cream for the treatment of intertrigo. [2 weeks]

    Side effects were calculated by the percentage of patients developed any side effects such as dryness, scaling, atrophy, and telangiectasia at week 2.

  2. Patients' satisfction of liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin, compared to topical 1% hydrocortisone cream for the treatment of intertrigo. [2 weeks]

    Satisfaction was measured on intertrigo lesion at the end of study visit by patients using visual analog scales (VAS). The minimum score is 0 (no satisfied) and the maximum score is 10 (most satisfied).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients who had age more than 18 years

  2. One intertrigo lesion at inframammary fold, inguinal region, interdigital, axilla or abdominal region with mild to moderate which only has erythema no epidermal loss

  3. Being diagnosed intertrigo by dermatologist. Patients will be clinical and investigational with KOH preparation and Wood's lamp diagnosed with intertrigo by dermatologist.

Exclusion Criteria:
  1. Patients receive topical steroids, topical anti-fungal drugs within 2 weeks prior the study

  2. Patients with skin conditions including fungal/bacterial infection, Hailey-Hailey disease, pemphigus, granuloma, psoriasis, acanthosis, or Darier disease on intertriginous areas within 2 weeks prior to the study

  3. Patients with an allergic to tapioca starch และ stimutex AS, aloe Barbadensis, rosa hip oil และ allantoin, or topical hydrocortisone

  4. Pregnant or breastfeeding women

  5. Patients with severe intertrigo treated with high potent topical steroid or systemic corticosteroid

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkoknoi Bangkok Thailand 10700

Sponsors and Collaborators

  • Mahidol University
  • HOE pharmaceuticals Sdn. Bhd.

Investigators

  • Principal Investigator: Kanokvalai Kulthanan, M.D., Mahidol University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mahidol University
ClinicalTrials.gov Identifier:
NCT04325490
Other Study ID Numbers:
  • Ezerra intertrigo
First Posted:
Mar 27, 2020
Last Update Posted:
Apr 20, 2021
Last Verified:
Apr 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mahidol University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2021